EUVIMEDEUVIMED entdecken
Klinische Studie

Immunogenicity of a single fractional intradermal dose of Japanese encephalitis live attenuated chimeric vaccine

Luis Furuya-Kanamori, Narayan Gyawali, Deborah J Mills, Christine Mills, Leon E Hugo, Gregor J Devine, Colleen L Lau

Journal of Travel Medicine · 2023

DOI: 10.1093/jtm/taac122 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Journal of Travel Medicine, 2023. Verfasst von Luis Furuya-Kanamori und 6 weiteren Autor:innen. Beteiligte Einrichtung: UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Herston, Australia. Hauptthemen laut MEDLINE: Encephalitis Virus, Japanese, Encephalitis, Japanese, Japanese Encephalitis Vaccines. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: NHMRC, National Health and Medical Research Council, International Society of Travel Medicine Research Awards.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Japanese encephalitis (JE) is endemic in Asia and the western Pacific. Vaccination is recommended for travellers to endemic regions, but the high cost of the vaccine is a major barrier to uptake.

Methods

A quasi-experimental, pre-post intervention clinical trial without a control group was conducted to assess the immunogenicity and safety of intradermal (ID) JE vaccine. Healthy adults (18–45 years) received one dose of 0.1 mL (20% of standard dose) ID Imojev® (JE live attenuated chimeric vaccine, Sanofi-Aventis). Adverse events following immunization (AEFIs) were recorded 10 days post-vaccination. Blood samples were collected at baseline, 4 and 8 weeks post-vaccination. Neutralizing antibodies were measured using 50% plaque reduction neutralization test (PRNT50). Seroconversion was defined as PRNT50 titre ≥10. An in vitro study was also conducted to quantify the rate of decay of vaccine potency after reconstitution.

Results

In total, 51 participants (72.6% females, median age 31 years), all non-reactive to JE virus at baseline were enrolled. Mild and moderate AEFIs were reported by 19.6% of participants; none required medical attention or interfered with normal daily activities. All participants seroconverted at 4 weeks (GMT 249.3; 95%CI:192.8–322.5) and remained seropositive at 8 weeks (GMT 135.5; 95%CI:104.5–175.6). Vaccine potency declined at a rate of 0.14 log plaque-forming units/0.5 mL per hour.

Conclusions

In healthy adults, a single 0.1 mL ID dose of Imojev was safe and immunogenic, at least in the short term. Reconstituted vials of Imojev vaccine may not retain their potency after 6 hours. Fractional JE ID vaccination could be a cheaper yet effective alternative for short-term travellers. Further studies need to investigate the immune response in a wider age range of individuals and the long-term immunogenicity of fractional JE ID vaccines. Clinical trials registration ACTRN12621000024842.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Encephalitis Virus, JapaneseEncephalitis, JapaneseJapanese Encephalitis VaccinesAdultFemaleHumansMaleAntibodies, ViralVaccines, Attenuated

Stichwörter der Autor:innen

ChimeriVaxJE-CVfractionalpotencyrecombinant

Substanzen

Antibodies, ViralJapanese Encephalitis VaccinesVaccines, Attenuated

Autor:innen und Institutionen

  • UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Herston, Australia.
  • Mosquito Control Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
  • Dr Deb The Travel Doctor, Travel Medicine Alliance, Brisbane, Australia.
  • School of Public Health, Faculty of Medicine, The University of Queensland, Herston, Australia.

Förderung

  • NHMRC
  • National Health and Medical Research Council
  • International Society of Travel Medicine Research Awards

Zitieren

APA

Furuya-Kanamori, L., Gyawali, N., Mills, D. J., Mills, C., Hugo, L. E., Devine, G. J., & Lau, C. L. (2023). Immunogenicity of a single fractional intradermal dose of Japanese encephalitis live attenuated chimeric vaccine. Journal of Travel Medicine. https://doi.org/10.1093/jtm/taac122

Vancouver

Furuya-Kanamori L, Gyawali N, Mills DJ, Mills C, Hugo LE, Devine GJ, et al. Immunogenicity of a single fractional intradermal dose of Japanese encephalitis live attenuated chimeric vaccine. Journal of Travel Medicine. 2023. doi:10.1093/jtm/taac122

BibTeX
@article{FuruyaKanamori2023,
  author = {Furuya-Kanamori, Luis and Gyawali, Narayan and Mills, Deborah J and Mills, Christine and Hugo, Leon E and Devine, Gregor J and Lau, Colleen L},
  title = {Immunogenicity of a single fractional intradermal dose of Japanese encephalitis live attenuated chimeric vaccine},
  journal = {Journal of Travel Medicine},
  year = {2023},
  doi = {10.1093/jtm/taac122}
}
Kostenlos starten →